BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA) announced the presentation of a progress update on the Company’s ongoing Phase 3 trial of Genasense® (oblimersen sodium) Injection, Genta’s lead oncology product, in patients with advanced melanoma. The data were presented in conjunction with the 27th Annual JP Morgan Healthcare Conference in San Francisco, CA.
